会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Novel Compounds
    • 新型化合物
    • US20070270435A1
    • 2007-11-22
    • US11743824
    • 2007-05-03
    • William BrownChristopher WalpoleNiklas PlobeckThomas Hudzik
    • William BrownChristopher WalpoleNiklas PlobeckThomas Hudzik
    • A61K31/496A61P25/24A61P43/00C07D295/00
    • C07D295/155C07D233/24C07D307/52C07D333/20
    • The invention relates to at least one compound of general formula I wherein R1 is phenyl, pyridinyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl, or pyridine N-oxide, where each R1 phenyl and R1 heteroaromatic ring may optionally and independently be substituted by 1, 2 or 3 substituents selected from CF3, methyl, iodo, bromo, fluoro, and chloro; R2 is independently selected from ethyl and isopropyl; R3 is hydrogen or fluoro; R4 is —NH2 or —NHSO2R5; and R5 is hydrogen, —CF3, or C1-C6 alkyl, or pharmaceutically acceptable salts thereof, at least one process for making at least one compound in accordance with Formula I; at least one method for treating at least one δ receptor associated condition with at least one compound in accordance with Formula I; and at least one pharmaceutical composition comprising at least one compound in accordance with Formula I.
    • 本发明涉及至少一种通式I的化合物,其中R 1是苯基,吡啶基,噻吩基,呋喃基,咪唑基,吡咯基,三唑基,噻唑基或吡啶N-氧化物,其中每个R 0 > 1苯基和R 1 - 杂芳环可以任选地和独立地被1,2或3个选自CF 3,甲基,碘,溴, 氟和氯; R 2独立地选自乙基和异丙基; R 3是氢或氟; R 4是-NH 2或-NHSO 2 R 5; 和R 5是氢,-CF 3或C 1 -C 6烷基,或其药学上可接受的盐 至少一种根据式I制备至少一种化合物的方法; 用至少一种根据式I的化合物治疗至少一种δ受体相关病症的方法; 和包含至少一种根据式I的化合物的至少一种药物组合物。
    • 10. 发明授权
    • Compounds
    • 化合物
    • US07915413B2
    • 2011-03-29
    • US11743824
    • 2007-05-03
    • William BrownChristopher WalpoleNiklas Plobeck
    • William BrownChristopher WalpoleNiklas Plobeck
    • C07D295/155C07D233/64C07D333/20C07D307/52
    • C07D295/155C07D233/24C07D307/52C07D333/20
    • The invention relates to at least one compound of general formula I wherein R1 is phenyl, pyridinyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl, or pyridine N-oxide, where each R1 phenyl and R1 heteroaromatic ring may optionally and independently be substituted by 1, 2 or 3 substituents selected from CF3, methyl, iodo, bromo, fluoro, and chloro; R2 is independently selected from ethyl and isopropyl; R3 is hydrogen or fluoro; R4 is —NH2 or —NHSO2R5; and R5 is hydrogen, —CF3, or C1-C6 alkyl, or pharmaceutically acceptable salts thereof, at least one process for making at least one compound in accordance with Formula I; at least one method for treating at least one δ receptor associated condition with at least one compound in accordance with Formula I; and at least one pharmaceutical composition comprising at least one compound in accordance with Formula I.
    • 本发明涉及至少一种通式I的化合物,其中R 1是苯基,吡啶基,噻吩基,呋喃基,咪唑基,吡咯基,三唑基,噻唑基或吡啶N-氧化物,其中每个R 1苯基和R 1杂芳环可任选地和独立地是 被1,2或3个选自CF 3,甲基,碘,溴,氟和氯的取代基取代; R2独立地选自乙基和异丙基; R3是氢或氟; R4是-NH2或-NHSO2R5; 和R 5是氢,-CF 3或C 1 -C 6烷基或其药学上可接受的盐,至少一种用于制备至少一种根据式I的化合物的方法; 用至少一种根据式I的化合物治疗至少一种δ受体相关病症的方法; 和包含至少一种根据式I的化合物的至少一种药物组合物。